BioSpace News Archive

Drug Development

Vivoryon’s Stock Craters After Alzheimer’s Candidate Fails Mid-Stage Trial

Varoglutamstat, a drug developed by German biotech Vivoryon Therapeutcs, did not hit its primary and secondary endpoints in a Phase IIb study in Alzheimer’s disease.

March 5, 2024
·
2 min read
·
Tyler Patchen
Deals

Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024

After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.

March 5, 2024
·
5 min read
·
Heather McKenzie
Deals

Biopharma VC Funding Value Dropped Nearly 20% in Q4 2023: Pitchbook

Companies inked 204 deals in the fourth quarter of 2023 with venture capital funding slipping to $6.3 billion from $7.8 billion in the third quarter last year, according to market data firm Pitchbook.

March 5, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Novo’s Ozempic Poised for Cardiometabolic Expansion with New Phase III Data

After stopping the study early due to strong efficacy, Novo Nordisk released data from the FLOW study showing significant benefits of semaglutide in patients with type 2 diabetes and chronic kidney disease.

March 5, 2024
·
2 min read
·
Tristan Manalac
Drug Delivery

Drug Price Negotiations Could Discourage Additional Approvals: Study

Examining 50 existing drugs, researchers find that the IRA could cause drug developers to shy away from pursuing subsequent indications for their marketed drugs, thereby reducing the number of new approvals.

March 5, 2024
·
5 min read
·
Adrianna Nine
Deals

Novartis, Ono Latest to Announce Billion-Dollar M&A Deals

Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.

March 5, 2024
·
24 min read
·
Neil Versel
FDA

Eyenovia, Formosa Win FDA Approval for Anti-Inflammatory Eye Drops

The regulator has approved Eyenovia and Formosa’s ophthalmic clobetasol propionate solution to ease eye inflammation and pain after surgery, with a potential $1.3 billion market.

March 5, 2024
·
2 min read
·
Tristan Manalac
Career Advice

How to Leverage the Right Resources to Craft an Effective Resume

Depending on their needs, candidates can choose among tools such as AI-powered resume generators, professional coaches and university career services to hone their applications.

March 5, 2024
·
5 min read
·
Sunitha Chari
FDA

Hugel Challenges Botox with FDA Approval for Neurotoxin Injection for Frown Lines

Hugel America has won the FDA’s approval for Letybo, authorized for the treatment of frown lines in adults, which is poised to challenge AbbVie’s blockbuster Botox.

March 5, 2024
·
2 min read
·
Tristan Manalac
Business

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Dyne Therapeutics, Inc. reported financial results for the fourth quarter and full year 2023 and recent business highlights.

March 5, 2024
·
10 min read